

Asciminib + Claritromycine

M 8427

Onderbouwend	Stof	Effect	Code
Hoch M. Clin Transl Sci. 2022;15:1698-1712.	asciminib + claritromycine	asciminib AUC 1.37x en Cmax 1.19x. Regime: asciminib 40 mg alleen of met claritromycine 500 mg 2dd; 14 gezonde vrijwilligers.	3A
Scemblix prod.label usa	asciminib + claritromycine	claritromycine: getallen als Hoch 2022.	2A

Overig	Stof	Effect
SPC Scemblix	asciminib + CYP3A4-remmers	CYP3A4-remmers, claritromycine: niet genoemd.
Scemblix prod.label usa	asciminib + CYP3A4-remmers	Closely monitor for adverse reactions during concomitant use of SCEMBLIX at 200 mg twice daily ((bij Ph+ CML in chronic phase with the T315I mutation; deze indicatie is wel door FDA goedgekeurd maar niet door EMA). No clinically significant differences in the pharmacokinetics of asciminib were observed when coadministered with itraconazole, which is also a strong CYP3A4 inhibitor.

Opmerkingen

Stockley online – claritromycine: severe, monitor

PubMed: geen aanvulling.

Risicofactoren	
Mitigerende factoren	

	Interactie	Actie	Datum
Beslissing WG Oncola	Ja	Nee	2 oktober 2024